卵巢上皮性癌ERCC1表达与顺铂化疗耐药关系的研究  

Study on the relation between the expression of ERCC1 and cisplatin resistance in ovarian epithelial carcinoma

作　　者：王会妍[1] 瞿全新[1] 

机构地区：[1]天津医科大学总医院妇产科,天津300052

出　　处：《现代妇产科进展》2006年第7期512-514,i0001,共4页Progress in Obstetrics and Gynecology

摘　　要：目的:探讨卵巢上皮性癌组织中ERCC1表达水平与顺铂化疗耐药的相关性。方法:应用免疫组化SP法检测42例卵巢癌组织中ERCC1的表达并分析其与顺铂化疗耐药的关系。结果:卵巢癌组织ERCC1表达水平与卵巢上皮性癌患者年龄、手术分期及组织学类型无关,而与卵巢上皮性癌患者以顺铂为基础联合化疗的耐药性有关。卵巢癌化疗耐药组ERCC1的阳性表达率为77.27%,明显高于敏感组35.00%,组间差异有统计学意义(P<0.05)。结论:ERCC1在卵巢上皮性癌组织中的表达水平与顺铂化疗耐药有关。Objective ：To determine the relation between the expression of ERCC1 and cisplatin resistance in ovarian epithelial carcinoma. Methods：The expression of ERCC1 was examined in 42 ovarian carcinoma tissues by Streptavidin-peroxidase complex technique and the relationship between the expression of ERCC1 and cisplatin resistance was analyzed by SPSSI2.0 statistical program. Results： Among those 42 cases, ERCC1 expression level did not show any association with patient age, clinical stage and histology type. The expression of ERCC1 was associated with cisplatin resistance in ovarian carcinoma tissues. The positive expression rate of ERCC1 in chemoresistant group was 77. 27% , that of chemosensitive one was 35.00%, with significant difference between the two groups （ P 〈 0.05 ）. Conclusion ： The expression of ERCC1 in ovarian epithelial carcinoma is related to cisplatin resistance, it shows predictive value to chemoresistance in ovarian carcinoma.

关 键 词：卵巢肿瘤 切除修复交叉互补基因 顺铂 抗药性 

分 类 号：R737.31[医药卫生—肿瘤]